University of Dundee intelligent drug design spinout Exscientia has struck a business deal with Celgene after raising series B funding from the corporate in January.

Exscientia, a UK-based small molecule discovery technology spinout of University of Dundee, received $25m today through a three-year drug design collaboration with pharmaceutical developer Celgene. The up-front payment could be augmented by additional funding on the fulfilment of milestones related to clinical, regulatory and commercial considerations. Exscientia will also receive tiered royalties on any product…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.